-
Mashup Score: 13AR and PI3K Genomic Profiling in Lutetium-177-PSMA Treatment: A Pathway to Identifying Poor Responders, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen review a study concerning AR and PI3K genomic profiling of cell-free DNA to identify poor responders to Lutetium-177-PSMA among mCRPC patients. This therapy is approved for patients whose disease has progressed following prior chemotherapy and androgen receptor signaling inhibitor, based on two Randomized Control Trials (RCTs): VISION and TheraP. These RCTs,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease - 7 month(s) ago
Rationale: The diagnosis of chronic obstructive pulmonary disease (COPD) is based on a low FEV1/FVC ratio, but the severity of COPD is classified using FEV1% predicted (ppFEV1). Objectives: To test…
Source: www.atsjournals.orgCategories: General Medicine News, Critical CareTweet-
RT @VCU_PCCM: #JournalClub Had a wonderful discussion on a new paper: https://t.co/FWexEYc67j @atscommunity @lkbrath @MichaeLheureux @c…
-
-
Mashup Score: 1cns.org - 7 month(s) ago
If need to reset your password. Click on the “Forgot Password” link. Enter your e-mail address and you will receive a password reset link sent to your email. If you do not receive an e-mail, check your spam folder or contact us at: info@cns.org If you have any other problems give us a call. Phone: 847-240-2500 …
Source: www.cns.orgCategories: Latest Headlines, NeurologyTweet-
November's Journal Club Podcast is out now! Listen to Christine Webber and Jenna-Lynn Senger compare TMR and RPNI to prevent neuroma pain and earn1.5 CME credits: https://t.co/stDdTAH6pA #CNSPodcasts #journalclub #podcasts @Dukeneurosurg @ThomasJWilsonMD @NeurosurgeryCNS https://t.co/D5udZMwpNb
-
-
Mashup Score: 0
Rashid Sayyid and Zach Klaassen discuss a study published in the Annals of Oncology, which delves into the clinical and transcriptomic heterogeneity of metastatic castration-sensitive prostate cancer (mCSPC). The study reveals important differences in patient prognosis based on disease volume and timing of metastases, with the worst prognosis found in synchronous high volume patients. The…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Transcriptomic and clinical heterogeneity in #mCSPC: Unraveling the molecular landscape. @RKSayyid @UofT & @zklaassen_md @GACancerCenter join in this UroToday #JournalClub discussion > https://t.co/eQoYGf77a9 @Annals_Oncology https://t.co/X1ffHtYpmz
-
-
Mashup Score: 0Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen analyze an ad hoc analysis from the VISION study, published in the Journal of Nuclear Medicine. The study investigates the agreement between readers in the interpretation of 68Ga-PSMA-11 PET/CT scans to determine patient eligibility for 177Lu-PSMA-617 Radioligand Therapy in the treatment of prostate cancer. They elaborate on the study’s methodology, including the…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Assessing reader variability in PSMA-PET/CT scan interpretation: a substudy of the #VISION trial. A #JournalClub discussion with @RKSayyid @UofT & @zklaassen_md @GACancerCenter on UroToday > https://t.co/AZFPcAgcNz https://t.co/TmhOwlc9am
-
-
Mashup Score: 2Improving mCRPC Outcomes: VISION Study Highlights Lu-PSMA-617 Impact on Survival and Quality of Life, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen, dissect a publication from the VISION study regarding health-related quality of life and pain outcomes with Lu-PSMA-617+ Standard of Care versus Standard of Care alone in patients with mCRPC. This study, conducted across 84 global centers, reveals that the addition of Lu-PSMA-617 to standard care significantly improved overall survival rates from 11.3 to 15.3…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Improving #mCRPC outcomes: #VISION Study highlights Lu-PSMA-617's impact on survival and QoL. @RKSayyid @UofT & @zklaassen_md @GACancerCenter join in this #JournalClub discussion on UroToday > https://t.co/l4Hs32h5c1 @TheLancetOncol https://t.co/S1bsIsvuX0
-
-
Mashup Score: 2October 2023 Journal Club Podcast: Digital Biomarkers and The Evolution of Spine Care Outcomes Measures: Smartphones and Wearables - 7 month(s) ago
How can spine surgeons leverage available technology to better assess their patients before and after surgery? In this episode, leaders in the field of neurosurgery discuss the article “Digital Biomar
Source: www.cns.orgCategories: Latest Headlines, NeurologyTweet-
Have you listened to the October episode of the Journal Club Podcast? Tune in to hear @ekoermann and @Hofstetter_MD discuss digital biomarkers and the evolution of spine care outcomes today: https://t.co/5qwQHtgx8T #CNSPodcast #JournalClub @Bsaway https://t.co/RVhU8R98iw
-
-
Mashup Score: 7AR and PI3K Genomic Profiling in Lutetium-177-PSMA Treatment: A Pathway to Identifying Poor Responders, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen review a study concerning AR and PI3K genomic profiling of cell-free DNA to identify poor responders to Lutetium-177-PSMA among mCRPC patients. This therapy is approved for patients whose disease has progressed following prior chemotherapy and androgen receptor signaling inhibitor, based on two Randomized Control Trials (RCTs): VISION and TheraP. These RCTs,…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
AR and PI3K genomic profiling in lutetium-177-PSMA treatment: a pathway to identifying poor responders. #JournalClub @RKSayyid @UofT and @zklaassen_md @GACancerCenter join to discuss on UroToday > https://t.co/aGg5GeqEQ5 @EurUrolOpen @Sj0mpie https://t.co/XafWOiwmw0
-
-
Mashup Score: 4Racial Differences in Prostate Cancer Germline Genetic Testing, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
In this Journal Club discussion, Rashid Sayyid and Zach Klaassen discuss the paper “Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review,” published in Equity in Cancer Care. The study focuses on the prevalence of genetic testing among different racial groups in the US, and finds significant racial disparities in the use of germline genetic testing for prostate…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Racial differences in #ProstateCancer germline #genetic testing. A #JournalClub discussion with @RKSayyid @UofT and @zklaassen_md @GACancerCenter on UroToday > https://t.co/Hy0ckUhOUh https://t.co/UEcKlLPbAm
-
-
Mashup Score: 5Tailoring Treatment Strategies: How a Nomogram Guides PSMA-PET Salvage Radiotherapy, Journal Club - Rashid Sayyid & Zachary Klaassen - 7 month(s) ago
Rashid Sayyid and Zach Klaassen discuss the development and validation of a multi-institutional nomogram for predicting outcomes of PSMA-PET-Based Salvage Radiotherapy in recurrent Prostate Cancer cases. Noting that 30-50% of high-risk patients experience biochemical failure within five years of radical prostatectomy, Drs. Sayyid and Klaassen highlight the increasing use of PSMA-PET/CT for…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Tailoring treatment strategies: how a nomogram guides PSMA-PET salvage radiotherapy. @RKSayyid @UofT and @zklaassen_md @GACancerCenter join in this #JournalClub discussion of this @JAMANetworkOpen publication on UroToday > https://t.co/ZAEWnYb7QY https://t.co/YcS6ZlElOL
-
AR and PI3K genomic profiling in lutetium-177-PSMA treatment: a pathway to identifying poor responders. #JournalClub @RKSayyid @UofT and @zklaassen_md @GACancerCenter join to discuss on UroToday > https://t.co/aGg5GeqEQ5 @EurUrolOpen @Sj0mpie https://t.co/XafWOiwmw0